Therapeutic Asset Ratings
409 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Idov-Immune
Ovarian Cancer
ViroMissile, Inc.
P1
C
(36)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Ovarian Cancer
SystImmune Inc.
P1
C
(36)
Innocell Autologous Cellular Immunotherapy
Ovarian Cancer
PhotonPharma, Inc.
P1
C
(36)
ivx037
Ovarian Cancer
ImmVirx Pty Ltd
P1
C
(36)
km1
Ovarian Cancer
Tongji Hospital
P1
C
(36)
Kras Tcr-Transduced Pbl
Ovarian Cancer
National Cancer Institute (NCI)
P1
C
(36)
Lncb74
Ovarian Cancer
NextCure, Inc.
P1
C
(36)
ly4052031
Ovarian Cancer
Eli Lilly and Company
P1
C
(36)
ly4101174
Ovarian Cancer
Eli Lilly and Company
P1
C
(36)
MGC026
Ovarian Cancer
MacroGenics
P1
C
(36)
MITOMYCIN C
Ovarian Cancer
National Cancer Institute (NCI)
P1
C
(36)
MNPR-101-DFO-89Zr
Ovarian Cancer
Monopar Therapeutics
P1
C
(36)
Mnpr-101-Pcta-177Lu
Ovarian Cancer
Monopar Therapeutics
P1
C
(36)
Moma-313
Ovarian Cancer
MOMA Therapeutics
P1
C
(36)
Naptumomab Estafenatox
Ovarian Cancer
NeoTX Therapeutics Ltd.
P1
C
(36)
Navitoclax
Ovarian Cancer
Sunnybrook Health Sciences Centre
P1
C
(36)
NeoOVIV
Ovarian Cancer
West China Hospital
P1
C
(36)
Neovax
Ovarian Cancer
Dana-Farber Cancer Institute
P1
C
(36)
Neratinib
Ovarian Cancer
Virginia Commonwealth University
P1
C
(36)
ngm438
Ovarian Cancer
NGM Biopharmaceuticals, Inc
P1
C
(36)
ngm831
Ovarian Cancer
NGM Biopharmaceuticals, Inc
P1
C
(36)
nkt3447
Ovarian Cancer
NiKang Therapeutics, Inc.
P1
C
(36)
nkt3964
Ovarian Cancer
NiKang Therapeutics, Inc.
P1
C
(36)
nm1f
Ovarian Cancer
Hefei TG ImmunoPharma Co., Ltd.
P1
C
(36)
Nms-03305293
Ovarian Cancer
Nerviano Medical Sciences
P1
C
(36)
Showing 326 to 350 of 409 assets
Previous
Page 14 of 17
Next